WO1998043630A1 - Means of ascertaining an individual's risk profile for atherosclerotic disease - Google Patents
Means of ascertaining an individual's risk profile for atherosclerotic disease Download PDFInfo
- Publication number
- WO1998043630A1 WO1998043630A1 PCT/US1998/006613 US9806613W WO9843630A1 WO 1998043630 A1 WO1998043630 A1 WO 1998043630A1 US 9806613 W US9806613 W US 9806613W WO 9843630 A1 WO9843630 A1 WO 9843630A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- marker
- level
- individual
- risk
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Definitions
- This invention describes the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention describes the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders.
- cardiovascular disease Despite significant advices in therapy, cardiovascular disease remains the single most common cause of morbidity and mortality in the developed world. Thus, prevention of cardiovascular disorders such as myocardial infarction and stroke is an area of major public health importance.
- screening tests include evaluations of total and HDL cholesterol levels.
- a large number of cardiovascular disorders occur in individuals with apparently low to moderate risk profiles, and our ability to identify such patients is limited.
- accumulating data suggests that the beneficial effects of certain preventive and therapeutic treatments for patients at risk for or known to have cardiovascular disorders differs in magnitude among different patient groups. At this time, however, data describing diagnostic tests to determine whether certain therapies can be expected to be more or less effective are lacking.
- Certain cardiovascular disorders such as myocardial infarction and ischemic stroke, are associated with atherosclerosis.
- the mechanism of atherosclerosis is not well understood. While inflammation is hypothesized to play a role in the initiation and progression of atherosclerosis, clinical data have not established whether inflammation increases, or anti- inflammatory treatments decrease, the risk of cardiovascular disorders associated with atherosclerosis.
- C-reactive protein is a marker for underlying systemic inflammation. Elevated levels of C-reactive protein have been described among patients with acute ischemia or myocardial infarction, and predict episodes of recurrent ischemia among those hospitalized with unstable angina. Further, plasma concentration of C-reactive protein is associated with risk of myocardial infarction among unhealthy patients, such as those with symptomatic angina pectoris. Plasma concentration of C-reactive protein also is associated with fatal, but not nonfatal, coronary heart disease among smokers with multiple risk factors for atherosclerosis.
- This invention describes new diagnostic tests which determine and utilize the magnitude of systemic inflammation. These new tests broadly include (1) the prediction of risk of future atherosclerotic disorders such as myocardial infarction and stroke and peripheral arterial disease; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat atherosclerotic disorders. These new tests are based in part upon the following discoveries. It has been discovered that elevated levels of markers of systemic inflammation are predictive of future cardiovascular disorders. For example, elevated levels of markers of systemic inflammation in apparently healthy, nonsmokers are predictive of an increased risk of myocardial infarction.
- elevated levels of markers of systemic inflammation in otherwise healthy smokers are predictive of an increased risk of a nonfatal myocardial infarction.
- elevated levels of markers of systemic inflammation are predictive of an increased likelihood of a future stroke. It has been discovered also that the likelihood that certain individuals will benefit to a greater or a lesser extent from the use of certain therapeutic agents for reducing the risk of a future cardiovascular disorder can be determined from the base-line level of systemic inflammation in an individual.
- markers of systemic inflammation are independent of other predictors and, for example, are additive with risk factors derived from total cholesterol levels and total cholesterol/HDL ratios.
- the level of markers of systemic inflammation does not simply duplicate that which is measured when levels of cholesterol are measured.
- a method for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of a cardiovascular disorder associated with atherosclerotic disease.
- the agent can be selected from the group consisting of anti-inflammatory agents, anti-thrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, and glycoprotein II b/IIIa receptor inhibitors and agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules (e.g. anti-cellular adhesion molecule antibodies).
- a preferred agent is aspirin).
- a level of a marker of systemic inflammation in an individual is obtained. This level then is compared to a predetermined value, wherein the level of the marker of systemic inflammation in comparison to the predetermined value is indicative of the likelihood that the individual will benefit from treatment with the agent. The individual then can be characterized in terms of the net benefit likely to be obtained by treatment with the agent.
- the predetermined value can be a single value, multiple values, a single range or multiple ranges.
- the predetermined value is a plurality of predetermined marker level ranges, and the comparing step comprises determining in which of the predetermined marker level ranges the individual's level falls.
- the individual is apparently healthy.
- the individual also is a nonsmoker.
- the marker of systemic inflammation is selected from the group consisting of C-reactive protein, a cytokine and a cellular adhesion molecule. In the most preferred embodiment, the marker of systemic inflammation is C-reactive protein. Particularly useful results have been obtained with this marker.
- a preferred predetermined value is about 1 3/4 mg/1 of blood. Another preferred predetermined value is about 2 mg/1 of blood. When ranges are employed, it is preferred that one of the plurality of ranges be below about 1 3/4 mg/1 of blood and that another of the ranges be above about 1 3/4 mg/1 of blood.
- a preferred predetermined value is about 250 ng/ml of blood. The predetermined value will depend, of course, on the particular marker selected and even upon the characteristics of the patient population in which the individual lies, described in greater detail below.
- the invention is particularly adapted to determining which individuals will preferentially benefit from treatment with an agent for reducing the risk in the individuals of a cardiovascular disorder such as a future stroke or a future myocardial infarction, including nonfatal myocardial infarctions. It also permits selection of candidate populations for clinical trials and for treatment with candidate drugs, by identifying, for example, the individuals most likely to benefit from a new treatment or from a known treatment with a high risk profile of adverse side effects. Thus, the invention provides information for evaluating the likely net benefit of certain treatments for candidate patients. According to another aspect of the invention, a method is provided for characterizing an apparently healthy, nonsmoking individual's risk profile of developing a future myocardial infarction.
- the method involves obtaining a level of a marker of systemic inflammation in the individual.
- the level of the marker then is compared to a predetermined value, and the individual's risk profile of developing a future myocardial infarction then is characterized based upon the level of the marker in comparison to the predetermined value.
- the predetermined value may be a single value, a plurality of values, a single range or a plurality of ranges.
- the predetermined value is a plurality of predetermined marker level ranges and the comparing step involves determining in which of the predetermined marker level ranges the individual's level falls.
- the preferred markers, predetermined values and the like are as described above.
- a method for characterizing an individual's risk profile of developing a future cardiovascular disorder associated with atherosclerotic disease, other than fatal myocardial infarction.
- a level of a marker of systemic inflammation in the individual is obtained.
- the level of the marker is compared to a predetermined value.
- the individual's risk profile of developing the future cardiovascular disorder associated with atherosclerotic disease, other than a fatal cardiovascular event then is characterized based upon the level of the marker in comparison to the predetermined value.
- the predetermined value can be as described above.
- the individual characterized may be any individual, but preferably is an apparently healthy individual.
- the apparently healthy individual can be a smoker or a nonsmoker.
- the preferred markers and predetermined values are as described above.
- the cardiovascular disorder is stroke.
- the cardiovascular disorder is nonfatal myocardial infarction.
- the cardiovascular disorder is peripheral artery disease.
- a method in which one uses an inflammatory marker together with a cholesterol fraction for characterizing an individual's risk profile of developing a future cardiovascular disorder associated with atherosclerotic disease.
- a level of a marker of systemic inflammation in the individual is obtained.
- the level of the marker is compared to a predetermined value to establish a first risk value.
- a level of a cholesterol in the individual also is obtained.
- the level of the cholesterol in the individual is compared to a second predetermined value to establish a second risk value.
- the individual's risk profile of developing the cardiovascular disorder then is characterized based upon the combination of the first risk value and the second risk value, wherein the combination of the first risk value and second risk value establishes a third risk value different from the first and second risk values.
- the third risk value is greater than either of the first and second risk values.
- the preferred individuals for testing, markers and predetermined values are as described above.
- the cardiovascular disorder can be any cardiovascular disorder associated with atherosclerotic disease, although in certain important embodiments the cardiovascular disorder is nonfatal myocardial infarction or ischemic stroke.
- kits comprising a package including an assay for a marker of systemic inflammation and instructions, and optionally related materials such as number or color charts, for correlating the level of the marker as determined by the assay with a risk of developing a future cardiovascular disorder or with other patient criteria as described above.
- the kits also include an assay for a cholesterol.
- the invention also involves a method for treating subjects, with anti-inflammatory therapies, to prevent cardiovascular disorders.
- a non-aspirin anti-inflammatory agent is administered to a subject who has an above-normal level of a marker of systemic inflammation, but who is otherwise free of symptoms calling for an anti-inflammatory agent.
- the anti- inflammatory agent is administered in an amount effective to lower the risk of the subject developing a future cardiovascular disorder.
- the preferred subjects are apparently healthy subjects free of current need for anti-inflammatory treatment, such as free of symptoms of rheumatoid arthritis, chronic back pain, autoimmune diseases, and the like.
- the invention also involves a method for treating subjects with agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules, to prevent cardiovascular disorders.
- Such an agent is administered to a subject, preferably who has an above-normal level of a marker of systemic inflammation, but who is otherwise free of symptoms calling to such an agent.
- the agent is administered as an amount effective to lower the risk of the subject developing a future cardiovascular disorder.
- the subject already has had a cardiovascular event, such as a heart attack or an angioplasty.
- the agent can limit further injury or help prevent restenosis, post-myocardial infarction and post angioplasty, respectively.
- the subjects are apparently healthy subjects free of current need for anti- inflammatory treatment such as free of symptoms of rheumatoid arthritis, chronic back pain, autoimmune disease, and the like.
- Figure 1 is a graph demonstrating the relative risk of first myocardial infarction in the study population according to baseline level of C-reactive protein. Data are shown for all study subjects and/or non-smokers.
- Figure 2 is a graph demonstrating the relative risks of future myocardial infarction associated with high, middle and low tertiles of total cholesterol and C-reactive protein.
- Figure 3 is a graph demonstrating the relative risks of future myocardial infarction associated with high, middle and low tertiles of total cholesterol :HDL cholesterol ratio and C- reactive protein.
- Figure 4 is a graph demonstrating relative risks (and 95 percent confidence interval) of first myocardial infarction associated with each increasing quartile of baseline C-reactive protein, according to year of study follow-up.
- Figure 5 is a graph demonstrating relative risks of first myocardial infarction associated with baseline levels of C-reactive protein, stratified by randomized assignment to aspirin or placebo therapy. Analyses are limited to events occurring prior to unblinding of the aspirin component of the Physicians' Health Study. The reduction in risk of myocardial infarction associated with aspirin use was 13.9 percent in the first (lowest) quartile of C-reactive protein, 33.4 percent in the second quartile, 46.3 percent in the third quartile, and 55.7 percent in the fourth (highest) quartile.
- Figure 6 is a graph demonstrating the distribution of levels of C-reactive protein in the population studied in Example. 1.
- Figure 7 is a graph demonstrating the normal bell curve distribution which occurs when the C-reactive protein levels of Fig. 5 are log normalized.
- the primary basis for this invention is evidence from the Physicians' Health Study, a large scale, randomized, double-blind, placebo controlled trial of aspirin and beta-carotene in the primary prevention of cardiovascular disease conducted among 22,000 apparently healthy men.
- baseline level of C reactive protein a marker for underlying systemic inflammation, was found to determine the future risk of myocardial infarction and stroke, independent of a large series of lipid and non-lipid risk factors.
- individuals with the highest baseline levels of C-reactive protein were found to have 3 fold increases in risk of developing future myocardial infarction and 2 fold increases in risk of developing future stroke. (Fig. 1).
- the current invention in one aspect describes the use of inflammatory markers to predict risk of cardiovascular disorders associated with atherosclerosis such as myocardial infarction and stroke among individuals without current evidence of disease.
- inflammatory markers such as C reactive protein to predict risk among already identified high-risk populations (such as smokers) or among symptomatic ischemia patients such as those with stable and unstable angina pectoris.
- Cardiovascular disorders associated with atherosclerotic disease includes myocardial infarction, stroke, angina pectoris and peripheral arteriovascular disease. Cardiovascular disorders associated with atherosclerotic disease do not include venous thrombosis.
- ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## a myocardial infarction i.e., individuals who are not at an elevated risk of a second adverse cardiovascular event due to a primary adverse cardiovascular event.
- Nonsmoking means an individual who, at the time of the evaluation, is not a smoker. This includes individuals who have never smoked as well as individuals who in the past have smoked but presently no longer smoke.
- Agents for reducing the risk of a cardiovascular disorder include those selected from the group consisting of anti-inflammatory agents, anti-thrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, and glycoprotein II b/IIIa receptor inhibitors and agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules (e.g. anti-cellular adhesion molecule antibodies).
- Anti-inflammatory agents include Alclofenac; Alclometasone Dipropionate; Algestone
- Benoxaprofen Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide;
- Carprofen Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide;
- Etofenamate Felbinac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolide Acetate; Flunixin ;
- Flunixin Meglumine Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen ;
- Fluretofen Fluticasone Propionate
- Furaprofen Furabufen
- Halcinonide Halobetasol
- Piconol Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen ; Indoxole ; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride ;
- Nimazone Olsalazine Sodium; Orgotein ; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium; Phenbutazone Sodium Glycerate;
- Pirfenidone Piroxicam
- Piroxicam Cinnamate Piroxicam Olamine
- Pirprofen Prednazate
- Anti-thrombotic and/or fibrinolytic agents include Plasminogen (to plasmin via interactions of prekallikrein, kininogens, Factors XII, XHIa, plasminogen proactivator, and tissue plasminogen activator[TPA]) Streptokinase; Urokinase: Anisoylated Plasminogen- Streptokinase Activator Complex; Pro-Urokinase; (Pro-UK); rTPA (alteplase or activase; r denotes recombinant); rPro-UK; Abbokinase; Eminase; Sreptase Anagrelide Hydrochloride; Bivalirudin; Dalteparin Sodium; Danaparoid Sodium; Dazoxiben Hydrochloride; Efegatran Sulfate; Enoxaparin Sodium; Ifetroban; Ifetroban Sodium; Tinzaparin Sodium; retaplase
- Anti-platelet agents include Clopridogrel; Sulfmpyrazone; Aspirin; Dipyridamole; Clofibrate; Pyridinol Carbamate; PGE; Glucagon; Antiserotonin drugs; Caffeine; Theophyllin
- Pentoxifyllin Ticlopidine; Anagrelide.
- Lipid reducing agents include gemfibrozil, cholystyramine, colestipol, nicotinic acid, probucol lovastatin, fluvastatin, simvastatin, atorvastatin, pravastatin, cirivastatin.
- Direct thrombin inhibitors include hirudin, hirugen, hirulog, agatroban, PPACK, thrombin aptamers.
- Glycoprotein Ilb/IIIa receptor Inhibitors are both antibodies and non-antibodies, and include but are not limited to ReoPro (abcixamab), lamifiban, tirofiban.
- One preferred agent is aspirin.
- markers of systemic inflammation are well- known to those of ordinary skill in the art. It is preferred that the markers of systemic inflammation be selected from the group consisting of C-reactive protein, cytokines, and cellular adhesion molecules. Cytokines are well-known to those of ordinary skill in the art and include human interleukins 1-17. Cellular adhesion molecules are well-known to those of ordinary skill in the art and include integrins, IC AM- 1 , IC AM-3 , BL-C AM, LF A-2, VC AM- 1 , NCAM, and PECAM.
- the preferred adhesion molecule is soluble intercellular adhesion molecule (sICAM-1).
- the level of the marker of systemic inflammation for the individual can be obtained by any art recognized method. Typically, the level is determined by measuring the level of the marker in a body fluid, for example, blood, lymph, saliva, urine and the like. The level can be determined by ELISA, or immunoassays or other conventional techniques for determining the presence of the marker. Conventional methods include sending samples of a patient's body fluid to a commercial laboratory for measurement.
- the invention also involves comparing the level of marker for the individual with a predetermined value.
- the predetermined value can take a variety of forms. It can be single cut-off value, such as a median or mean. It can be established based upon comparative groups, such as where the risk in one defined group is double the risk in another defined group. It can be a range, for example, where the tested population is divided equally (or unequally) into groups, such as a low-risk group, a medium-risk group and a high-risk group, or into quadrants, the lowest quadrant being individuals with the lowest risk and the highest quadrant being individuals with the highest risk.
- the predetermined value can depend upon the particular population selected.
- an apparently healthy, nonsmoker population (no detectable disease and no prior history of a cardiovascular disorder) will have a different 'normal' range of markers of systemic inflammation than will a smoking population or a population the members of which have had a prior cardiovascular disorder.
- the predetermined values selected may take into account the category in which an individual falls. Appropriate ranges and categories can be selected with no more than routine experimentation by those of ordinary skill in the art.
- polypeptide agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules include polypeptide agents.
- polypeptide agents include polyclonal and monoclonal antibodies, prepared according to conventional methodology. Such antibodies already are known in the art and include anti-ICAM 1 antibodies as well as other such antibodies.
- anti-ICAM 1 antibodies as well as other such antibodies.
- the pFc' and Fc regions are effectors of the complement cascade but are not involved in antigen binding.
- An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F9ab') 2 fragment retains both of the antigen binding sites of an intact antibody.
- an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region designated an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule.
- Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd.
- the Fd fragments are the major determinant of antibody specificity ( a single Fd Fragment may be associated with up to ten different light chains without altering antibody specific
- CDRs complementarity determining regions
- Frs framework regions
- FR1 through FR4 framework regions
- CDR1 through CDR3 complementarity determining regions
- the present invention also provides for F(ab') 2 , Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or Fr and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab') 2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or nonhuman sequences.
- the present invention also includes so-called single chain antibodies.
- the invention involves polypeptides of numerous size and type that bind specifically to cellular adhesion molecules.
- polypeptides may be derived also from sources other than antibody technology.
- polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries.
- Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.
- Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. ml3, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures.
- the inserts may represent, for example, a completely degenerate or biased array.
- the minimal linear portion of the sequence that binds to the cellular adhesion molecule can be determined.
- Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the cellular adhesion molecules.
- cellular adhesion molecules, or a fragment thereof can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the cellular adhesion molecules.
- the preferred body fluid is blood and the preferred marker is C-reactive protein.
- C- reactive protein one important cut-off for a population of apparently healthy, nonsmokers is 1.75 mg/liter (median). Another important cut-off for C-reactive protein is 2.0 mg/liter (highest quartile of risk). In characterizing risk, numerous predetermined values can be established. In the preferred embodiment employing C-reactive protein, the cut-off values described above, and in greater detail in the example below, are surprisingly lower than those shown in the prior art where C-reactive protein levels are studied in unhealthy individuals or smokers.
- the invention provides novel kits or assays which are specific for, and have appropriate sensitivity with respect to, predetermined values selected on the basis of the present invention.
- the preferred kits therefore, would differ from those presently commercially available, by including, for example, different cut-offs, different sensitivities at particular cut-offs as well as instructions or other printed material for characterizing risk based upon the outcome of the assay.
- the invention provides methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing risk of a future cardiovascular disorder. This method has important implications for patient treatment and also for clinical development of new therapeutics. Physicians select therapeutic regimens for patient treatment based upon the expected net benefit to the patient. The net benefit is derived from the risk to benefit ratio.
- the present invention permits selection of individuals who are more likely to benefit by intervention, thereby aiding the physician in selecting a therapeutic regimen. This might include using drugs with a higher risk profile where the likelihood of expected benefit has increased.
- clinical investigators desire to select for clinical trials a population with a high likelihood of obtaining a net benefit. The present invention can help clinical investigators select such individuals. It is expected that clinical investigators now will use the present invention for determining entry criteria for clinical trials.
- markers of systemic inflammation have predictive value independent of other known predictors of future adverse cardiovascular disorders.
- the present invention does not involve simply duplicating a measurement that previously could be made using other predictors.
- the markers of systemic inflammation are additive to prior art predictors. This is illustrated in Figs 2 and 3, wherein the data of the present invention is analyzed to characterize the risk profiles of individuals, taking into account, both total cholesterol levels and levels of C-reactive protein.
- Fig 2 shows the relative risk of future myocardial infarction associated with high, middle and low tertiles of total cholesterol and C reactive protein.
- the invention also involves a method for treating subjects, with anti-inflammatory therapies, to prevent cardiovascular disorders.
- a non-aspirin anti-inflammatory agent is administered to a subject who has an above-normal level of a marker of systemic inflammation, but who is otherwise free of symptoms calling for an anti-inflammatory agent.
- the anti- inflammatory agent is administered in an effective amount.
- An effective amount is a dosage of the anti-inflammatory agent sufficient to provide a medically desirable result.
- the effective amount will vary with the particular condition being treated, the age and physical condition of the subject being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration and the like factors within the knowledge and expertise of the health practioner. For example, an effective amount can depend upon the degree to which an individual has abnormally elevated levels of markers of systemic information. It should be understood that the anti-inflammatory agents of the invention are used to prevent cardiovascular disorders, that is, they are used prophylactically in subjects at risk of developing a cardiovascular disorder. Thus, an effective amount is that amount which can lower the risk of, slow or perhaps prevent altogether the development of a cardiovascular disorder.
- the agent When the agent is one that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, then the agent may be used prophylactically or may be used in acute circumstances, for example, post-myocardial infarction or post-angioplasty. It will be recognized when the agent is used in acute circumstances, it is used to prevent one or more medically undesirable results that typically flow from such adverse events.
- the agent In the case of myocardial infarction, the agent can be used to limit injury to the cardiovascular tissue which develops as a result of the myocardial infarction and in the case of restinosis the agent can be used in amounts effective to inhibit, prevent or slow the reoccurrence of blockage. In either case, it is an amount sufficient to inhibit the infiltration of white blood cells and transmigration of white blood cells into the damaged tissue, which white blood cells can result in further damage and/or complications relating to the injury.
- doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable, preferably orally and in one or several administrations per day. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds.
- the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptably compositions.
- Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
- the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.
- pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
- the anti-inflammatory agents may be combined, optionally, with a pharmaceutically- acceptable carrier.
- pharmaceutically-acceptable carrier means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration into a human.
- carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- the components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.
- the pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
- suitable buffering agents including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
- compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
- suitable preservatives such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
- compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the anti-inflammatory agent, which is preferably isotonic with the blood of the recipient.
- This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example, as a solution in 1,3-butane diol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- fatty acids such as oleic acid may be used in the preparation of injectables.
- Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
- a variety of administration routes are available. The particular mode selected will depend, of course, upon the particular drug selected, the severity of the condition being treated and the dosage required for therapeutic efficacy.
- the methods of the invention may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
- modes of administration include oral, rectal, topical, nasal, interdermal, or parenteral routes.
- parenteral includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis. They could, however, be preferred in emergency situations. Oral administration will be preferred for prophylactic treatment because of the convenience to the patient as well as the dosing schedule.
- compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the anti-inflammatory agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the anti-inflammatory agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
- compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the anti- inflammatory agent.
- Other compositions include suspensions in aqueous liquids or non- aqueous liquids such as a syrup, elixir or an emulsion.
- Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the anti-inflammatory agent, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art.
- polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides.
- Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109.
- Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like.
- erosional systems in which the anti-inflammatory agent is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,667,014, 4,748,034 and 5,239,660 and (b) difusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,832,253, and 3,854,480.
- pump-based hardware delivery systems can be used, some of which are adapted for implantation.
- Long-term sustained release means that the implant is constructed and arranged to delivery therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days.
- Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.
- EXAMPLE Study Organization The Physicians' Health Study is a randomized, double-blind, placebo controlled, 2 x 2 factorial trial of aspirin and beta-carotene in the primary prevention of cardiovascular disease and cancer.
- Subject recruitment A total of 22,071 US male physicians aged 40 to 84 years in 1982 with no history of myocardial infarction, stroke, transient ischemic attack, or cancer were assigned to one of four treatment groups: 325 mg aspirin on alternate days (Bufferin, provided by Bristol-Myers), 50 mg of beta-carotene on alternate days (Lurotin, provided by BASF Corporation), both, or neither.
- the aspirin component of the PHS was terminated early on January 25, 1988 primarily due to a statistically extreme 44 percent reduction in risk of first infarction in the aspirin group. 1
- the beta-carotene component continued to scheduled termination on December 31, 1995.
- Reported deep venous thrombosis was confirmed by documentation of a positive venography study or a positive ultrasound study; deep venous thrombosis documented only by impedance plethysmography or Doppler examination without ultrasound were not confirmed.
- Reported pulmonary embolism was confirmed by positive angiogram or completed ventilation- perfusion scan demonstrating at least two segmental perfusion defects with normal ventilation.
- Each participant who provided an adequate baseline plasma sample and had a confirmed myocardial infarction, stroke, or venous thrombosis after randomization was matched to one control. Controls were participating physicians who provided baseline plasma samples and reported no cardiovascular disease at the time the case reported his event.
- Controls were randomly selected from study participants who met the matching criteria of age (+/- one year), smoking habit (current, past, or never), and time since randomization (six month intervals). Using these methods, we evaluated 543 cases and 543 controls in this prospective nested case- control design.
- Means or proportions for baseline risk factors were calculated for cases and controls. The significance of any difference in means was tested using the Student's t-test and the significance of any differences in proportions tested using the Chi square statistic. Because C- reactive protein levels are skewed, median levels were computed and the significance of any differences in median values between cases and controls assessed using Wilcoxon's Rank Sum Test. Geometric mean C-reactive protein levels were also computed after log transformation which resulted in near normal distribution. Tests for trends were used to assess any relationship of increasing levels of C-reactive protein with risks of future vascular disease after dividing the sample into quartiles defined by the distribution of the control values.
- Adjusted estimates were obtained using conditional logistic regression models accounting for the matching variables and controlling for randomized treatment assignment, body mass index, diabetes, history of hypertension, and a parental history of coronary artery disease. Similar models were employed to adjust for measured baseline levels of total and HDL cholesterol, triglyceride, lipoprotein(a), tPA antigen, fibrinogen, D-dimer, and homocysteine. To evaluate whether aspirin affected these relationships, analyses were repeated for all myocardial infarction events occurring on or before January 25, 1988, the date of termination of randomized aspirin assignment. All P values were two-tailed and confidence intervals calculated at the 95 percent level.
- Table 1 shows baseline characteristics of study participants. As expected, those who subsequently developed myocardial infarction were more likely than those who remained free of vascular disease to have a history of hypertension, hyperlipidemia, or a parental history of coronary artery disease. Similarly, those who subsequently developed stroke were more likely to be hypertensive. Due to the matching, age and smoking were similar in cases and controls.
- Table 2 Baseline levels of C-reactive protein among study participants who remained free of vascular disease during follow-up (controls) and among those who developed myocardial infarction, stroke, or venous thrombosis (cases)
- Table 3 Relative risks of future myocardial infarction, stroke, and venous thrombosis according to baseline levels of C-reactive protein.
- C-reactive protein was not significantly altered in analyses which adjusted for body mass index, diabetes, hypertension, a family history of premature coronary artery disease, total cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), tPA antigen, D-dimer, fibrinogen, or homocysteine (Table 5).
- C-reactive protein might be a predictor of risk over and above that associated with cholesterol levels.
- C-reactive protein was found to predict risk of future myocardial infarction among those with low as well as high levels of total cholesterol, and among those with low as well as high total cholesterol to HDL cholesterol ratios.
- C- reactive protein are addictive to that of cholesterol.
- tertile low, middle, or high
- Similar analyses were performed in which study subject were characterized by tertile of the total cholesterol to HDL cholesterol ratio. As shown in Figures 2 and 3, the risks of myocardial infarction associate with C-reactive protein appear addictive to that of lipid parameters alone.
- the actual C-reactive protein levels for the tested population are shown graphically in Fig. 6.
- the log normalized C-reactive protein levels are shown in Fig. 7, which demonstrates clearly the normal bell curve distribution in our population.
- the mean C-reactive protein was 1.75 and the standard deviation was 2.2.
- the mean of the log C-reactive protein was about .1 and the standard deviation was about 1.
- Table 6 shows the relative risks (RR) of future myocardial infarction according to baseline levels of s-ICAM-1. A statistically significant association was observed.
- the relationship between s-ICAM and myocardial infarction also is not significantly altered in analysis which adjusted for body mass index, diabetes, a family history of premature coronary artery disease, hyperlipidemia, and a history of hypertension.
- C-reactive protein is related to atherothrombosis.
- Prior infection with Chlamydia pnuemoniae, Heliobacter pylori, Herpes simplex virus, or cytomegalovirus may be a source of the chronic inflammation detected by C-reactive protein. 13"19
- C-reactive protein is a surrogate for interleukin-6 20 , a cellular cytokine associated with macrophage and monocyte recruitment into atherosclerotic plaque. 21
- C-reactive protein can induce monocytes to express tissue-factor, a membrane glycoprotein important in the initiation of coagulation.
- C-reactive protein predicts risk of first myocardial infarction and ischemic stroke, independent of other risk factors.
- baseline C-reactive protein level is not associated with venous thrombosis, a vascular event generally not associated with atherosclerosis.
- C-reactive protein is not simply a short term marker as previously demonstrated for patients with unstable angina 12 , but also a long term marker of risk, even for events occurring after 6 or more years. This observation suggests that the effects of inflammation are likely mediated through a chronic process, and excludes the possibility that undetected acute illness at baseline is responsible for observed effects.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU71008/98A AU7100898A (en) | 1997-04-02 | 1998-04-02 | Means of ascertaining an individual's risk profile for atherosclerotic disease |
CA002285091A CA2285091A1 (en) | 1997-04-02 | 1998-04-02 | Means of ascertaining an individual's risk profile for atherosclerotic disease |
AT98917992T ATE290375T1 (en) | 1997-04-02 | 1998-04-02 | USE OF AN AGENT FOR REDUCING THE RISK OF CARDIOVASCULAR DISEASES |
JP1998542023A JP3805381B6 (en) | 1997-04-02 | 1998-04-02 | A means to confirm an individual's risk profile for atherosclerotic disease |
EP98917992A EP1003501B9 (en) | 1997-04-02 | 1998-04-02 | Use of an agent for lowering the risk of cardiovascular disease |
DE69829293T DE69829293T2 (en) | 1997-04-02 | 1998-04-02 | USE OF A MEANS TO REDUCE THE RISK OF CARDIOVASCULAR DISEASES |
DK98917992T DK1003501T3 (en) | 1997-04-02 | 1998-04-02 | Use of a means to reduce the risk of cardiovascular disease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4195097P | 1997-04-02 | 1997-04-02 | |
US4303997P | 1997-04-02 | 1997-04-02 | |
US60/043,039 | 1997-04-02 | ||
US60/041,950 | 1997-04-02 | ||
US7089498P | 1998-01-09 | 1998-01-09 | |
US60/070,894 | 1998-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998043630A1 true WO1998043630A1 (en) | 1998-10-08 |
Family
ID=27366025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006613 WO1998043630A1 (en) | 1997-04-02 | 1998-04-02 | Means of ascertaining an individual's risk profile for atherosclerotic disease |
Country Status (12)
Country | Link |
---|---|
US (1) | US6040147A (en) |
EP (4) | EP1003501B9 (en) |
JP (3) | JP2008120800A (en) |
AT (2) | ATE290375T1 (en) |
AU (1) | AU7100898A (en) |
CA (1) | CA2285091A1 (en) |
CY (1) | CY1112261T1 (en) |
DE (1) | DE69829293T2 (en) |
DK (2) | DK1003501T3 (en) |
ES (2) | ES2239801T3 (en) |
PT (2) | PT1003501E (en) |
WO (1) | WO1998043630A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001015744A1 (en) * | 1999-08-31 | 2001-03-08 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
JP2003516541A (en) * | 1999-12-10 | 2003-05-13 | ユニヴェルシテ ドゥ ジュネーブ | Diagnostic assays for seizures |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
EP1520590A1 (en) * | 1999-08-31 | 2005-04-06 | The Brigham and Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
US6878698B2 (en) | 2001-04-07 | 2005-04-12 | Glaxo Group Limited | Anti-inflammatory androstane derivatives |
WO2005046675A2 (en) * | 2003-11-07 | 2005-05-26 | Jordan Holtzman | Methods for enhancing glutathione peroxidase activity |
WO2005110422A2 (en) * | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
US7030152B1 (en) | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US7125985B2 (en) | 2000-08-05 | 2006-10-24 | Glaxo Group Limited | Compounds useful in the manufacture of an anti-inflammatory androstane derivative |
US7189518B2 (en) | 2001-11-05 | 2007-03-13 | The Brigham And Women's Hospital, Inc. | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
EP1767223A1 (en) * | 1999-08-31 | 2007-03-28 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
WO2007094200A1 (en) * | 2006-02-14 | 2007-08-23 | Pola Chemical Industries Inc. | Skin-whitening cosmetic |
US7608406B2 (en) | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
WO2009138437A1 (en) * | 2008-05-13 | 2009-11-19 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
WO2010014771A1 (en) * | 2008-08-01 | 2010-02-04 | Ore Pharmaceuticals Inc. | Romazarit for treating metabolic diseases |
US7723049B2 (en) | 2001-01-12 | 2010-05-25 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
US8027791B2 (en) | 2004-06-23 | 2011-09-27 | Medtronic, Inc. | Self-improving classification system |
US8335652B2 (en) | 2004-06-23 | 2012-12-18 | Yougene Corp. | Self-improving identification method |
US8603829B2 (en) | 2009-09-09 | 2013-12-10 | Hitachi Ltd. | Atherosclerosis marker and use thereof |
US9164104B2 (en) | 2004-10-06 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
WO2018060556A1 (en) * | 2016-09-29 | 2018-04-05 | Oy Medix Biochemica Ab | Method for determining risks associated with cardiovascular diseases |
US11312994B2 (en) | 2014-05-05 | 2022-04-26 | Medtronic, Inc | Methods and compositions for SCD, CRT, CRT-D, or SCA therapy identification and/or selection |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US6321164B1 (en) | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
US6898532B1 (en) | 1995-06-07 | 2005-05-24 | Biomerieux, Inc. | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
US6727102B1 (en) * | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
US6502040B2 (en) | 1997-12-31 | 2002-12-31 | Biomerieux, Inc. | Method for presenting thrombosis and hemostasis assay data |
ATE253223T1 (en) * | 1998-08-27 | 2003-11-15 | Mayo Foundation | METHODS AND MATERIALS FOR DIAGNOSING UNSTABLE ANGINA |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
ATE282208T1 (en) * | 1999-02-04 | 2004-11-15 | Bio Merieux Inc | METHOD AND APPARATUS FOR PREDICTING HEMOSTATIC FUNCTION IN PATIENT SAMPLES |
US7179612B2 (en) * | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
US8101363B2 (en) * | 2000-12-14 | 2012-01-24 | The Brigham And Women's Hospital, Inc. | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes |
US6855509B2 (en) * | 2000-12-19 | 2005-02-15 | Instrumentation Laboratory Company | Protein S functional assay and kit therefor |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
EP1353666B1 (en) | 2001-01-02 | 2013-07-03 | The Cleveland Clinic Foundation | Myeloperoxidase, a risk indicator for cardiovascular disease |
US20020151536A1 (en) * | 2001-01-26 | 2002-10-17 | Schering Corporation | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
EP1401456A4 (en) * | 2001-02-21 | 2005-04-20 | Merck & Co Inc | Method fron determining the efficacy of reverse cholesterol transport enhancing agents |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
JP2005504091A (en) * | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | Treatment of xanthomas with azetidinone as a sterol absorption inhibitor |
CA2465900A1 (en) * | 2001-11-09 | 2003-05-15 | Medstar Research Institute | Method of using physiological markers to estimate cardiovascular risk |
WO2003043570A2 (en) | 2001-11-15 | 2003-05-30 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
US20040071633A1 (en) * | 2002-02-19 | 2004-04-15 | Wright Samuel D. | Method for determining efficacy of reverse cholesterol transport enhancing agents |
ES2685697T3 (en) | 2002-05-09 | 2018-10-10 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 as a marker of cardiovascular diseases |
US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US7145025B2 (en) * | 2002-07-29 | 2006-12-05 | Hawaii Biotech, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
US7521584B2 (en) * | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
NZ569868A (en) | 2002-09-27 | 2010-01-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
WO2005027886A2 (en) * | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
US7851486B2 (en) * | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
US7507531B2 (en) * | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
AU2003291012A1 (en) * | 2002-11-15 | 2004-06-15 | Galileo Pharmaceuticals, Inc. | Chroman derivatives for the reduction of inflammation symptoms |
EP1575567A4 (en) * | 2002-12-12 | 2008-10-08 | Activbiotics Inc | Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
US20050026168A1 (en) * | 2002-12-13 | 2005-02-03 | Genesis Group Inc. | Method for the detection of risk factors associated with myocardial infarction |
GB0229747D0 (en) * | 2002-12-20 | 2003-01-29 | Axis Shield Asa | Assay |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7208486B2 (en) * | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009503A (en) * | 2003-03-07 | 2005-10-18 | Schering Corp | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia. |
US20040192660A1 (en) * | 2003-03-12 | 2004-09-30 | Mullally John P. | Protocol for improving vision |
WO2004080414A2 (en) * | 2003-03-12 | 2004-09-23 | Mullally John P | Composition and method for treating inflammations by reducing c-reactive protein |
US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
EP1673465A4 (en) * | 2003-09-29 | 2008-04-30 | Biosite Inc | Methods and compositions for the diagnosis of sepsis |
US20080085329A1 (en) * | 2003-10-22 | 2008-04-10 | Fred Hutchinson Cancer Research Center, Inc. | Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms |
US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
US20070238655A1 (en) * | 2003-11-12 | 2007-10-11 | The Trustees Of The University Of Pennsylvania | Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis |
CA2549236C (en) | 2003-12-05 | 2017-06-13 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
US20080279843A1 (en) * | 2003-12-09 | 2008-11-13 | Essential Skincare, Llc | Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
US20050250745A1 (en) * | 2004-02-25 | 2005-11-10 | Seddon Johanna M | Biomarkers for age-related macular degeneration (AMD) |
EP1750723A1 (en) * | 2004-04-14 | 2007-02-14 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
EP1755661B1 (en) * | 2004-05-12 | 2014-03-12 | The Brigham And Women's Hospital, Inc. | Gelsolin for use in treating infections |
US9372190B2 (en) * | 2004-05-26 | 2016-06-21 | Region Nordjylland | Method of evaluation of the relative risk of developing atherosclerosis in patients |
US20060020043A1 (en) * | 2004-07-26 | 2006-01-26 | Roger Berlin | Methods and compositions for reducing C-reactive protein |
US7378396B2 (en) | 2004-08-11 | 2008-05-27 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
WO2006031592A1 (en) * | 2004-09-09 | 2006-03-23 | University Of Massachusetts | Disease markers for early stage atherosclerosis |
AU2005284830A1 (en) * | 2004-09-13 | 2006-03-23 | Lipomics Technologies, Inc. | Metabolite markers for weight management |
CA2595067A1 (en) * | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
PT1879599E (en) * | 2005-04-20 | 2014-01-23 | Hutchinson Fred Cancer Res | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
EP2368561B1 (en) * | 2005-04-29 | 2013-12-04 | The Regents of The University of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
PL2001496T3 (en) * | 2006-03-15 | 2017-10-31 | Brigham & Womens Hospital Inc | Use of gelsolin to diagnose and treat inflammatory diseases |
US8440622B2 (en) * | 2006-03-15 | 2013-05-14 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel) |
ES2646142T3 (en) | 2006-04-24 | 2017-12-12 | Critical Care Diagnostics, Inc. | Evaluation of the efficacy of a treatment in a subject based on ST2 levels |
EP2021799B1 (en) * | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
PL2021796T3 (en) * | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnosis of cardiovascular disease |
WO2007131031A2 (en) * | 2006-05-02 | 2007-11-15 | Critical Care Diagnostics, Inc. | Diagnosis of pulmonary and/or cardiovascular disease |
EP2924440A3 (en) | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
US20100105088A1 (en) * | 2007-02-05 | 2010-04-29 | Aarhus Universitet | method for diagnosing atherosclerotic plaques by measurement of cd36 |
AU2008296487A1 (en) | 2007-08-28 | 2009-03-12 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
DK2682400T5 (en) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Synthetic apolipoprotein E mimic polypeptides and methods of use |
WO2009032722A1 (en) * | 2007-08-29 | 2009-03-12 | The Cleveland Clinic Foundation | Carbamylated proteins and risk of cardiovascular disease |
US9423405B2 (en) * | 2007-12-05 | 2016-08-23 | The Cleveland Clinic Foundation | Trimethylamine compounds as risk predictors of cardiovascular disease |
US9575072B2 (en) | 2008-01-25 | 2017-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic and therapeutic uses of gelsolin in renal failure |
WO2009129454A2 (en) | 2008-04-18 | 2009-10-22 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
US11835503B2 (en) | 2009-05-28 | 2023-12-05 | The Cleveland Clinic Foundation | TMA-formation inhibitor treatment for elevated TMA-containing compound diseases |
US10241093B2 (en) | 2009-05-28 | 2019-03-26 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
JP5728488B2 (en) * | 2009-11-13 | 2015-06-03 | ビージー メディシン, インコーポレイテッド | Risk factors and prediction of myocardial infarction |
WO2012141844A2 (en) | 2011-03-17 | 2012-10-18 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
US8708906B1 (en) * | 2011-09-07 | 2014-04-29 | Allen J. Orehek | Method for the prevention of dementia and Alzheimer's disease |
CA2882303A1 (en) | 2012-08-21 | 2014-02-27 | Critical Care Diagnostics, Inc. | Multimarker risk stratification |
EP3556850A1 (en) * | 2012-12-12 | 2019-10-23 | Mesoblast, Inc. | Treatment of diseases of endothelial dysfunction and inflammation |
MX2017001432A (en) | 2014-07-31 | 2017-05-09 | Uab Res Found | Apoe mimetic peptides and higher potency to clear plasma cholesterol. |
US10328045B2 (en) | 2014-09-12 | 2019-06-25 | Children's Medical Center Corporation, Inc. | Dietary emulsion formulations and methods for using the same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4287202A (en) * | 1978-05-26 | 1981-09-01 | Horrobin David F | Treatment and/or prophylaxis of spasms of coronary arteries |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
JPS60139621A (en) * | 1983-12-27 | 1985-07-24 | Grelan Pharmaceut Co Ltd | Antithrombotic agent |
JPS625970A (en) * | 1985-03-15 | 1987-01-12 | Terumo Corp | Pyrazine derivative and platelet coagulation inhibitor containing same |
US4902630A (en) * | 1985-07-22 | 1990-02-20 | Abbott Laboratories | Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5003065A (en) * | 1988-06-14 | 1991-03-26 | Carey Merritt | Compounds and process for measuring c-reactive protein |
US5500345A (en) * | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
US5272258A (en) * | 1989-06-29 | 1993-12-21 | Rush-Presbyterian-St. Luke's Medical Center | Monoclonal antibodies to C-reactive protein |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
JPH04167172A (en) | 1990-10-31 | 1992-06-15 | Nec Corp | Vector processor |
-
1998
- 1998-04-02 AT AT98917992T patent/ATE290375T1/en active
- 1998-04-02 WO PCT/US1998/006613 patent/WO1998043630A1/en active IP Right Grant
- 1998-04-02 ES ES98917992T patent/ES2239801T3/en not_active Expired - Lifetime
- 1998-04-02 AT AT04010424T patent/ATE530180T1/en active
- 1998-04-02 AU AU71008/98A patent/AU7100898A/en not_active Abandoned
- 1998-04-02 PT PT98917992T patent/PT1003501E/en unknown
- 1998-04-02 CA CA002285091A patent/CA2285091A1/en not_active Abandoned
- 1998-04-02 DK DK98917992T patent/DK1003501T3/en active
- 1998-04-02 US US09/054,212 patent/US6040147A/en not_active Expired - Lifetime
- 1998-04-02 ES ES04010424T patent/ES2374621T3/en not_active Expired - Lifetime
- 1998-04-02 DK DK04010424.2T patent/DK1493439T3/en active
- 1998-04-02 EP EP98917992A patent/EP1003501B9/en not_active Revoked
- 1998-04-02 EP EP20100185029 patent/EP2305236A1/en not_active Ceased
- 1998-04-02 EP EP10185011A patent/EP2305235A1/en not_active Withdrawn
- 1998-04-02 EP EP04010424A patent/EP1493439B1/en not_active Expired - Lifetime
- 1998-04-02 PT PT04010424T patent/PT1493439E/en unknown
- 1998-04-02 DE DE69829293T patent/DE69829293T2/en not_active Expired - Lifetime
-
2007
- 2007-10-26 JP JP2007279272A patent/JP2008120800A/en active Pending
-
2012
- 2012-01-24 CY CY20121100083T patent/CY1112261T1/en unknown
- 2012-08-02 JP JP2012172186A patent/JP2013036996A/en not_active Withdrawn
-
2014
- 2014-12-11 JP JP2014250860A patent/JP2015079003A/en active Pending
Non-Patent Citations (2)
Title |
---|
BIOLOGICAL ABSTRACTS, 1 January 1900, Philadelphia, PA, US; abstract no. 79:244445, XP002910417 * |
HAVERKATE F., ET AL.: "C-REACTIVE PROTEIN AND CARDIOVASCULAR DISEASE.", FIBRINOLYSIS AND PROTEOLYSIS, NEW YORK, NY, US, vol. 11., no. SUPPL. 01., 3 May 1996 (1996-05-03), US, pages 133/134., XP002910416, ISSN: 1369-0191 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030152B1 (en) | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US7964614B2 (en) | 1997-04-02 | 2011-06-21 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
WO2001015744A1 (en) * | 1999-08-31 | 2001-03-08 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
JP2003508453A (en) * | 1999-08-31 | 2003-03-04 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerosis |
EP1767223A1 (en) * | 1999-08-31 | 2007-03-28 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
AU782386C (en) * | 1999-08-31 | 2006-08-10 | Brigham And Women's Hospital | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
EP1767222A1 (en) * | 1999-08-31 | 2007-03-28 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
AU782386B2 (en) * | 1999-08-31 | 2005-07-21 | Brigham And Women's Hospital | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
EP1520590A1 (en) * | 1999-08-31 | 2005-04-06 | The Brigham and Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
JP2003516541A (en) * | 1999-12-10 | 2003-05-13 | ユニヴェルシテ ドゥ ジュネーブ | Diagnostic assays for seizures |
JP4751555B2 (en) * | 1999-12-10 | 2011-08-17 | エレクトロフォレティックス リミテッド | Diagnostic assays for stroke |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US7125985B2 (en) | 2000-08-05 | 2006-10-24 | Glaxo Group Limited | Compounds useful in the manufacture of an anti-inflammatory androstane derivative |
US7132532B2 (en) | 2000-08-05 | 2006-11-07 | Glaxo Group Limited | Compounds useful in the manufacture of an anti-inflammatory androstane derivative |
US7144845B2 (en) | 2000-08-05 | 2006-12-05 | Glaxo Group Limited | Compounds useful in the manufacture of an anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US8323913B2 (en) | 2001-01-12 | 2012-12-04 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
US7939280B2 (en) | 2001-01-12 | 2011-05-10 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
US7723049B2 (en) | 2001-01-12 | 2010-05-25 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
US6878698B2 (en) | 2001-04-07 | 2005-04-12 | Glaxo Group Limited | Anti-inflammatory androstane derivatives |
US7608406B2 (en) | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7189518B2 (en) | 2001-11-05 | 2007-03-13 | The Brigham And Women's Hospital, Inc. | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
WO2005046675A2 (en) * | 2003-11-07 | 2005-05-26 | Jordan Holtzman | Methods for enhancing glutathione peroxidase activity |
WO2005046675A3 (en) * | 2003-11-07 | 2005-09-22 | Jordan Holtzman | Methods for enhancing glutathione peroxidase activity |
WO2005110422A2 (en) * | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
US7393843B2 (en) | 2004-05-19 | 2008-07-01 | Boehringer Ingelheim International Gmbh | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds |
US7534787B2 (en) | 2004-05-19 | 2009-05-19 | Boehringer Ingelheim International Gmbh | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds |
US7375220B2 (en) | 2004-05-19 | 2008-05-20 | Boehringer Ingelheim Vetmedica Gmbh | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds |
WO2005110422A3 (en) * | 2004-05-19 | 2006-05-18 | Boehringer Ingelheim Int | Treatment of diseases associated with altered level of amyloid beta peptides |
US8027791B2 (en) | 2004-06-23 | 2011-09-27 | Medtronic, Inc. | Self-improving classification system |
US8335652B2 (en) | 2004-06-23 | 2012-12-18 | Yougene Corp. | Self-improving identification method |
US9164104B2 (en) | 2004-10-06 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
US11435363B2 (en) | 2004-10-06 | 2022-09-06 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
WO2007094200A1 (en) * | 2006-02-14 | 2007-08-23 | Pola Chemical Industries Inc. | Skin-whitening cosmetic |
WO2009138437A1 (en) * | 2008-05-13 | 2009-11-19 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
WO2010014771A1 (en) * | 2008-08-01 | 2010-02-04 | Ore Pharmaceuticals Inc. | Romazarit for treating metabolic diseases |
US8603829B2 (en) | 2009-09-09 | 2013-12-10 | Hitachi Ltd. | Atherosclerosis marker and use thereof |
US11312994B2 (en) | 2014-05-05 | 2022-04-26 | Medtronic, Inc | Methods and compositions for SCD, CRT, CRT-D, or SCA therapy identification and/or selection |
WO2018060556A1 (en) * | 2016-09-29 | 2018-04-05 | Oy Medix Biochemica Ab | Method for determining risks associated with cardiovascular diseases |
Also Published As
Publication number | Publication date |
---|---|
EP1493439B1 (en) | 2011-10-26 |
DK1003501T3 (en) | 2005-07-18 |
EP2305236A1 (en) | 2011-04-06 |
JP2013036996A (en) | 2013-02-21 |
ES2374621T3 (en) | 2012-02-20 |
DE69829293T2 (en) | 2006-04-13 |
CA2285091A1 (en) | 1998-10-08 |
EP1003501A1 (en) | 2000-05-31 |
EP1003501B1 (en) | 2005-03-09 |
ATE290375T1 (en) | 2005-03-15 |
JP2008120800A (en) | 2008-05-29 |
DE69829293D1 (en) | 2005-04-14 |
PT1493439E (en) | 2012-01-10 |
ES2239801T3 (en) | 2005-10-01 |
EP1003501B9 (en) | 2005-06-08 |
JP2001525058A (en) | 2001-12-04 |
ATE530180T1 (en) | 2011-11-15 |
JP3805381B2 (en) | 2006-08-02 |
EP1493439A1 (en) | 2005-01-05 |
EP1003501A4 (en) | 2001-01-17 |
EP2305235A1 (en) | 2011-04-06 |
JP2015079003A (en) | 2015-04-23 |
AU7100898A (en) | 1998-10-22 |
CY1112261T1 (en) | 2015-12-09 |
US6040147A (en) | 2000-03-21 |
DK1493439T3 (en) | 2012-01-30 |
PT1003501E (en) | 2005-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6040147A (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | |
US7964614B2 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | |
JP4950895B2 (en) | PIGF and Flt-1 as prognostic parameters for cardiovascular disease | |
US7189518B2 (en) | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases | |
AU2005294165B2 (en) | Relevance of achieved levels of markers of systemic inflammation following treatment | |
AU782386B2 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
WO2003088811A2 (en) | Gelsolin as a prognostic marker of artherosclerotic diseases | |
JP3805381B6 (en) | A means to confirm an individual's risk profile for atherosclerotic disease | |
EP1520590A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
EP1767223A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
JP2003128582A (en) | Means for confirming dangerous profile of individual related to atherosclerosis disease | |
AU2005225101A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclered diseases | |
AU2002343620A1 (en) | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2285091 Country of ref document: CA Ref country code: CA Ref document number: 2285091 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 542023 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998917992 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998917992 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998917992 Country of ref document: EP |